Page 43«..1020..42434445..5060..»

Codex DNA Announces Plan to Change Corporate Name to Telesis Bio

By Dr. Matthew Watson

Novel name reflects expansion of capabilities and solutions Novel name reflects expansion of capabilities and solutions

Go here to see the original:
Codex DNA Announces Plan to Change Corporate Name to Telesis Bio

To Read More: Codex DNA Announces Plan to Change Corporate Name to Telesis Bio
categoriaGlobal News Feed commentoComments Off on Codex DNA Announces Plan to Change Corporate Name to Telesis Bio | dataOctober 13th, 2022
Read All

Axiom Exhibiting at Outsourcing in Clinical Trials New England 2022

By Dr. Matthew Watson

TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting at Outsourcing in Clinical Trials New England 2022, October 12-13 in Boston, MA.

Read this article:
Axiom Exhibiting at Outsourcing in Clinical Trials New England 2022

To Read More: Axiom Exhibiting at Outsourcing in Clinical Trials New England 2022
categoriaGlobal News Feed commentoComments Off on Axiom Exhibiting at Outsourcing in Clinical Trials New England 2022 | dataOctober 13th, 2022
Read All

Loos, France, Isovital Headquarter, Oct 12th 2022 – Radiopharma Logistics Group (RLG); ISOTOPES SERVICES INTERNATIONAL (ISI). NEW SHAREHOLDER

By Dr. Matthew Watson

Loos, France, Isovital Headquarter, Oct 12th 2022 - Radiopharma Logistics Group (RLG); ISOTOPES SERVICES INTERNATIONAL (ISI). NEW SHAREHOLDERClaude Poliart, founder and manager of the logistic company « Road Runner » was acting as a consultant for ISI until now and becomes ISOTOPES SERVICES INTERNATIONAL (ISI) shareholder.

View original post here:
Loos, France, Isovital Headquarter, Oct 12th 2022 - Radiopharma Logistics Group (RLG); ISOTOPES SERVICES INTERNATIONAL (ISI). NEW SHAREHOLDER

To Read More: Loos, France, Isovital Headquarter, Oct 12th 2022 – Radiopharma Logistics Group (RLG); ISOTOPES SERVICES INTERNATIONAL (ISI). NEW SHAREHOLDER
categoriaGlobal News Feed commentoComments Off on Loos, France, Isovital Headquarter, Oct 12th 2022 – Radiopharma Logistics Group (RLG); ISOTOPES SERVICES INTERNATIONAL (ISI). NEW SHAREHOLDER | dataOctober 13th, 2022
Read All

Hyloris Pharmaceuticals Announces Move to LégiaPark Complex Aligned with its Sustainable Growth Strategy and Support of Social Well-Being for its…

By Dr. Matthew Watson

Liège, Belgium – 12 October 2022 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announced it has moved its headquartered operations to LégiaPark, in the heart of the life sciences industry ecosystem of Liege, within the Wallonia region. LégiaPark is a new modern complex operating with environmental responsibility and hosts life science companies.

Original post:
Hyloris Pharmaceuticals Announces Move to LégiaPark Complex Aligned with its Sustainable Growth Strategy and Support of Social Well-Being for its...

To Read More: Hyloris Pharmaceuticals Announces Move to LégiaPark Complex Aligned with its Sustainable Growth Strategy and Support of Social Well-Being for its…
categoriaGlobal News Feed commentoComments Off on Hyloris Pharmaceuticals Announces Move to LégiaPark Complex Aligned with its Sustainable Growth Strategy and Support of Social Well-Being for its… | dataOctober 13th, 2022
Read All

Derm-Biome Pharmaceuticals, Inc. reports positive preclinical data in melanoma and squamous cell carcinoma, initiates a program aimed at advancing…

By Dr. Matthew Watson

VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin health and healthy aging, has initiated a program aimed at advancing its topical treatments for precancerous skin conditions such as actinic keratosis and non-melanoma skin cancers such as squamous cell carcinoma through to the clinic. One in every three cancers diagnosed worldwide is skin cancer, with non-melanoma skin cancers the most common of all types of cancer, representing a significant market opportunity. According to a report by Grand View Research, Inc, the global actinic keratosis treatment market size alone is expected to reach $8.12 billion USD by 2028.

Here is the original post:
Derm-Biome Pharmaceuticals, Inc. reports positive preclinical data in melanoma and squamous cell carcinoma, initiates a program aimed at advancing...

To Read More: Derm-Biome Pharmaceuticals, Inc. reports positive preclinical data in melanoma and squamous cell carcinoma, initiates a program aimed at advancing…
categoriaGlobal News Feed commentoComments Off on Derm-Biome Pharmaceuticals, Inc. reports positive preclinical data in melanoma and squamous cell carcinoma, initiates a program aimed at advancing… | dataOctober 13th, 2022
Read All

VectivBio Announces Date of Extraordinary General Meeting of Shareholders

By Dr. Matthew Watson

BASEL, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the date of the Extraordinary General Meeting, which will be held on Friday, December 9, 2022, at 10:00 a.m. CEST / 4:00 a.m. EDT at the offices of VectivBio Holding AG at Aeschenvorstadt 36, 4051 Basel, Switzerland.

View post:
VectivBio Announces Date of Extraordinary General Meeting of Shareholders

To Read More: VectivBio Announces Date of Extraordinary General Meeting of Shareholders
categoriaGlobal News Feed commentoComments Off on VectivBio Announces Date of Extraordinary General Meeting of Shareholders | dataOctober 13th, 2022
Read All

Araris Biotech AG Appoints Filippo Mulinacci, Ph.D., MBA as Chief Business Officer

By Dr. Matthew Watson

AU ZH, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, is pleased to announce the appointment of Filippo Mulinacci, Ph.D., MBA as chief business officer.

Read more here:
Araris Biotech AG Appoints Filippo Mulinacci, Ph.D., MBA as Chief Business Officer

To Read More: Araris Biotech AG Appoints Filippo Mulinacci, Ph.D., MBA as Chief Business Officer
categoriaGlobal News Feed commentoComments Off on Araris Biotech AG Appoints Filippo Mulinacci, Ph.D., MBA as Chief Business Officer | dataOctober 13th, 2022
Read All

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through…

By Dr. Matthew Watson

NEW YORK and MAINZ, GERMANY, OCTOBER 12, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for a 10-µg booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 5 through 11 years of age. Pending recommendation from the Centers for Disease Control and Prevention (CDC), 10-µg doses will be shipped immediately.

See the rest here:
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through...

To Read More: Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through…
categoriaGlobal News Feed commentoComments Off on Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through… | dataOctober 13th, 2022
Read All

COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day

By Dr. Matthew Watson

First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022 First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022

See more here:
COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day

To Read More: COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day
categoriaGlobal News Feed commentoComments Off on COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day | dataOctober 13th, 2022
Read All

Biosenta Inc. Enters into an MOU with Voran Group Ventures Ltd. to collaborate on the commercialization of Biosenta’s Tri-Filler® Products

By Dr. Matthew Watson

CALGARY, Alberta, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Biosenta Inc. (the “Company” or “Biosenta”) (CSE: ZRO) has signed a milestone Memorandum of Understanding dated October 5, 2022, with VORAN GROUP VENTURES Ltd. (“Voran”) which will lead the way for the commercialization of Biosenta’s Tri-Filler® antimicrobial products in Canadian markets and worldwide.

Here is the original post:
Biosenta Inc. Enters into an MOU with Voran Group Ventures Ltd. to collaborate on the commercialization of Biosenta’s Tri-Filler® Products

To Read More: Biosenta Inc. Enters into an MOU with Voran Group Ventures Ltd. to collaborate on the commercialization of Biosenta’s Tri-Filler® Products
categoriaGlobal News Feed commentoComments Off on Biosenta Inc. Enters into an MOU with Voran Group Ventures Ltd. to collaborate on the commercialization of Biosenta’s Tri-Filler® Products | dataOctober 13th, 2022
Read All

Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022

By Dr. Matthew Watson

WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD), formerly Adagio Therapeutics (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases announced today that it will have four poster presentations at ID Week 2022. The posters will share findings from several studies surrounding adintrevimab, including data from the Phase 1 and Phase 2/3 clinical trials.

See the original post here:
Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022

To Read More: Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022
categoriaGlobal News Feed commentoComments Off on Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022 | dataOctober 13th, 2022
Read All

U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced…

By Dr. Matthew Watson

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced today that, as disclosed on uspto.gov, the United States Patent and Trademark Office (“USPTO”) has allowed U.S. Patent Application No. 17/720,619, titled “Use of Tivozanib to Treat Subjects with Refractory Cancer” (the “Application”). AVEO expects to receive a Notice of Allowance for this Application. This Application will potentially issue as a patent in 2022 and will provide patent protection in the United States for the claimed methods of use of FOTIVDA into 2039.

See the article here:
U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced...

To Read More: U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced…
categoriaGlobal News Feed commentoComments Off on U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced… | dataOctober 13th, 2022
Read All

SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox

By Dr. Matthew Watson

NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox.

Follow this link:
SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox

To Read More: SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox
categoriaGlobal News Feed commentoComments Off on SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox | dataOctober 13th, 2022
Read All

23andMe to Present at Upcoming Investor Conferences

By Dr. Matthew Watson

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be participating in investor presentations at the following conferences:

View original post here:
23andMe to Present at Upcoming Investor Conferences

To Read More: 23andMe to Present at Upcoming Investor Conferences
categoriaGlobal News Feed commentoComments Off on 23andMe to Present at Upcoming Investor Conferences | dataOctober 13th, 2022
Read All

AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

By Dr. Matthew Watson

Company expects to commence patient enrollment and dosing in Q1 2023 Company expects to commence patient enrollment and dosing in Q1 2023

Here is the original post:
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

To Read More: AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions
categoriaGlobal News Feed commentoComments Off on AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions | dataOctober 13th, 2022
Read All

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

By Dr. Matthew Watson

•  No safety concerns noted in ongoing clinical trial•  Study timeline remains on track

Go here to see the original:
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

To Read More: Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
categoriaGlobal News Feed commentoComments Off on Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2 | dataOctober 13th, 2022
Read All

BioSyent Initiates First Dividend

By Dr. Matthew Watson

MISSISSAUGA, Ontario, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on December 15, 2022, to shareholders of record at the close of business on November 30, 2022. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.

Read more here:
BioSyent Initiates First Dividend

To Read More: BioSyent Initiates First Dividend
categoriaGlobal News Feed commentoComments Off on BioSyent Initiates First Dividend | dataOctober 13th, 2022
Read All

Enterin and Parkinson’s UK Announce Research Collaboration in Parkinson’s Dementia

By Dr. Matthew Watson

PHILADELPHIA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative and metabolic diseases announces a collaboration with the Parkinson’s Virtual Biotech, the drug development and discovery arm of Parkinson's UK. A new phase 2 trial will study the effects of ENT-01 on Parkinson’s Disease (PD)-associated dementia.

Go here to see the original:
Enterin and Parkinson’s UK Announce Research Collaboration in Parkinson’s Dementia

To Read More: Enterin and Parkinson’s UK Announce Research Collaboration in Parkinson’s Dementia
categoriaGlobal News Feed commentoComments Off on Enterin and Parkinson’s UK Announce Research Collaboration in Parkinson’s Dementia | dataOctober 13th, 2022
Read All

ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China

By Dr. Matthew Watson

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

See the rest here:
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China

To Read More: ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
categoriaGlobal News Feed commentoComments Off on ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China | dataOctober 13th, 2022
Read All

Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus…

By Dr. Matthew Watson

Basel/Allschwil, Switzerland, October 13, 2022

Read the original post:
Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus...

To Read More: Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus…
categoriaGlobal News Feed commentoComments Off on Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus… | dataOctober 13th, 2022
Read All

Page 43«..1020..42434445..5060..»


Copyright :: 2024